TrialInvestigational new drugs2014

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study.

Tien Hoang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.